183 related articles for article (PubMed ID: 21426837)
1. [Challenge and treatment strategy for ocular surface damage in patients with long term use of antiglaucoma drugs].
He XG
Zhonghua Yan Ke Za Zhi; 2011 Feb; 47(2):101-4. PubMed ID: 21426837
[TBL] [Abstract][Full Text] [Related]
2. Preservatives in eyedrops: the good, the bad and the ugly.
Baudouin C; Labbé A; Liang H; Pauly A; Brignole-Baudouin F
Prog Retin Eye Res; 2010 Jul; 29(4):312-34. PubMed ID: 20302969
[TBL] [Abstract][Full Text] [Related]
3. [Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe].
Levrat F; Pisella PJ; Baudouin C
J Fr Ophtalmol; 1999 Mar; 22(2):186-91. PubMed ID: 10327349
[TBL] [Abstract][Full Text] [Related]
4. [Managing treatment side effects: the respective roles of the active ingredient and the preservative].
Aptel F; Denis P; Baudouin C
J Fr Ophtalmol; 2011 Jun; 34(6):409-12. PubMed ID: 21511364
[TBL] [Abstract][Full Text] [Related]
5. [Ocular surface injury resulted from topical anti-glaucoma medications: prevention and cure].
Ouyang PB; Duan XC
Zhonghua Yan Ke Za Zhi; 2012 Jun; 48(6):557-61. PubMed ID: 22943813
[TBL] [Abstract][Full Text] [Related]
6. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.
Baudouin C
Acta Ophthalmol; 2008 Nov; 86(7):716-26. PubMed ID: 18537937
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic Effects of Sodium Hyaluronate on Ocular Surface Damage Induced by Benzalkonium Chloride Preserved Anti-glaucoma Medications.
Liu X; Yu FF; Zhong YM; Guo XX; Mao Z
Chin Med J (Engl); 2015 Sep; 128(18):2444-9. PubMed ID: 26365960
[TBL] [Abstract][Full Text] [Related]
8. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.
Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E
Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302
[TBL] [Abstract][Full Text] [Related]
9. [Glaucoma and ocular surface].
Stefan C; Cojocaru I; Pop A
Oftalmologia; 2011; 55(1):30-3. PubMed ID: 21774383
[TBL] [Abstract][Full Text] [Related]
10. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
Hommer A; Mohammed Ramez O; Burchert M; Kimmich F
Curr Med Res Opin; 2010 Aug; 26(8):1905-13. PubMed ID: 20553122
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of failure in glaucoma filtering surgery: a consequence of antiglaucomatous drugs?
Baudouin C
Int J Clin Pharmacol Res; 1996; 16(1):29-41. PubMed ID: 9001927
[TBL] [Abstract][Full Text] [Related]
12. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies.
Baudouin C; Pisella PJ; Fillacier K; Goldschild M; Becquet F; De Saint Jean M; Béchetoille A
Ophthalmology; 1999 Mar; 106(3):556-63. PubMed ID: 10080214
[TBL] [Abstract][Full Text] [Related]
13. [Ocular intolerance to antiglaucoma medications is underestimated].
Bresson-Dumont H
Bull Soc Belge Ophtalmol; 2010; (315):47-53. PubMed ID: 21114054
[TBL] [Abstract][Full Text] [Related]
14. [Structural and immunohistochemical changes of conjunctiva induced by topical glaucoma medication].
Nenciu A; Stefan C; Ardelean C
Oftalmologia; 2004; 48(1):35-42. PubMed ID: 15279417
[TBL] [Abstract][Full Text] [Related]
15. [Advances in preservative-free glaucoma drops].
Stefan C; Pop A; Cojocaru I
Oftalmologia; 2011; 55(2):3-6. PubMed ID: 21888063
[TBL] [Abstract][Full Text] [Related]
16. Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study.
Liang H; Baudouin C; Labbe A; Riancho L; Brignole-Baudouin F
PLoS One; 2012; 7(3):e33913. PubMed ID: 22442734
[TBL] [Abstract][Full Text] [Related]
17. [Morphological alterations induced by preservatives in eye drops].
Huber-van der Velden KK; Thieme H; Eichhorn M
Ophthalmologe; 2012 Nov; 109(11):1077-81. PubMed ID: 23179812
[TBL] [Abstract][Full Text] [Related]
18. Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.
Ammar DA; Noecker RJ; Kahook MY
Adv Ther; 2010 Nov; 27(11):837-45. PubMed ID: 20931366
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications.
Fechtner RD; Godfrey DG; Budenz D; Stewart JA; Stewart WC; Jasek MC
Cornea; 2010 Jun; 29(6):618-21. PubMed ID: 20386433
[TBL] [Abstract][Full Text] [Related]
20. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
